SCHEMBL20839465

SCHEMBL20839465

Cc1ccsc1-c1cc(=O)oc2cc(O[C@H](C)C(=O)NC(C)C)ccc12

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.56
▸ KDM4E B2RXH2 6/20 0.56
▸ HPGD P15428 5/20 0.56
▸ HSD17B10 Q99714 3/20 0.56
▸ ALDH2 P05091 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ RAB9A P51151 1/20 0.49
▸ RECQL P46063 1/20 0.49
▸ KMT2A Q03164 2/20 0.48
▸ GAA P10253 1/20 0.48
▸ AR P10275 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20839467 1.00 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDHSD17B10ALDH2
SCHEMBL30763228 1.00 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDHSD17B10ALDH2
SCHEMBL22431741 0.87 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDHSD17B10ALDH2
SCHEMBL20839158 0.84 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDHSD17B10ALDH2
SCHEMBL30360969 0.84 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDHSD17B10ALDH2
SCHEMBL20839155 0.84 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDHSD17B10ALDH2
SCHEMBL20839109 0.83 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10ALDH2
SCHEMBL30763039 0.83 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10ALDH2
SCHEMBL20839413 0.83 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10ALDH2
SCHEMBL30762875 0.83 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10ALDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 — — US claimed
EP-4333822-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION Lead Discovery Center GmbH (DE) 2024-03-13 — — EP claimed
WO-2022233782-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2022-11-10 — — WO claimed
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION LEAD DISCOVERY CENTER GMBH (DE) 2024-08-01 — — US disclosed
CN-111386261-B Coumarin derivatives, process for their preparation and their use in the treatment of cancer 利德发现中心有限责任公司 2024-03-22 — — CN disclosed
EP-3684762-B1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2023-05-03 — — EP disclosed
EP-3684762-B1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2023-05-03 — — EP disclosed
US-11111238-B2 Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2021-09-07 — — US disclosed
US-11111238-B2 Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer LEAD DISCOVERY CENTER GMBH (DE) 2021-09-07 — — US disclosed
US-20200291011-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-09-17 — — US disclosed
US-20200291011-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-09-17 — — US disclosed
EP-3684762-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-07-29 — — EP disclosed
CN-111386261-A Coumarin derivatives, preparation method thereof and application thereof in cancer treatment 利德发现中心有限责任公司 2020-07-07 — — CN disclosed
WO-2019057821-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2019-03-28 — — WO disclosed
WO-2019057821-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2019-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252454-A1 COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION TFAM, POLRMT, TUFM ALDH1A1 3415/4885KDM4E 1030/4885HPGD 1853/4885
US-11111238-B2 Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer POLRMT, UQCRC2, UQCRC1 ALDH1A1 1261/4885KDM4E 2362/4885HPGD 947/4885
US-20200291011-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER POLRMT, UQCRC2, UQCRC1 ALDH1A1 1261/4885KDM4E 2362/4885HPGD 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback